These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 11505337)

  • 21. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.
    Snoeck E; Wade JR; Duff F; Lamb M; Jorga K
    Br J Clin Pharmacol; 2006 Dec; 62(6):699-709. PubMed ID: 17118125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice.
    Lee SS; Bain VG; Peltekian K; Krajden M; Yoshida EM; Deschenes M; Heathcote J; Bailey RJ; Simonyi S; Sherman M;
    Aliment Pharmacol Ther; 2006 Feb; 23(3):397-408. PubMed ID: 16422999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Injection site with generalized rash caused by pegylated interferon alpha 2a injection.
    Kawada K; Maeda N; Kobayashi S; Sowa J; Tsuruta D; Kawada N
    Dermatology; 2006; 212(1):82-3. PubMed ID: 16319482
    [No Abstract]   [Full Text] [Related]  

  • 25. Hepatitis C virus therapy to date.
    Foster G; Mathurin P
    Antivir Ther; 2008; 13 Suppl 1():3-8. PubMed ID: 18432157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegylated interferon (PEG-Intron) for chronic hepatitis C.
    Med Lett Drugs Ther; 2001 Jun; 43(1107):54-5. PubMed ID: 11426190
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].
    Son BK; Sohn JH; Kim TY; Park YK; Jeon YC; Han DS
    Korean J Hepatol; 2007 Mar; 13(1):103-7. PubMed ID: 17380081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiviral effect of peginterferon alfa-2b and alfa-2a compared.
    Jansen PL; Reesink HW
    J Hepatol; 2006 Aug; 45(2):172-3. PubMed ID: 16797101
    [No Abstract]   [Full Text] [Related]  

  • 29. [Combination therapy for chronic viral hepatitis C].
    Zeuzem S
    Dtsch Med Wochenschr; 2003 Feb; 128(8):370-4. PubMed ID: 12594622
    [No Abstract]   [Full Text] [Related]  

  • 30. [Therapy of hepatitis C].
    Moradpour D; Blum HE
    Praxis (Bern 1994); 2002 May; 91(22):977-82. PubMed ID: 12094432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials.
    Chalasani N; Manzarbeitia C; Ferenci P; Vogel W; Fontana RJ; Voigt M; Riely C; Martin P; Teperman L; Jiao J; Lopez-Talavera JC;
    Hepatology; 2005 Feb; 41(2):289-98. PubMed ID: 15660392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation.
    Mukherjee S
    Transplant Proc; 2005 Dec; 37(10):4403-5. PubMed ID: 16387131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A case of Bell's palsy associated with peginterferon Alfa-2a and ribavirin therapy for chronic hepatitis C virus infection].
    Lee MY; Cho H; Kim YM; Lee JS
    Korean J Hepatol; 2006 Sep; 12(3):444-8. PubMed ID: 16998297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Genotype 1 superresponder treat for only 24 weeks].
    MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of hepatitis C.
    Heathcote J; Main J
    J Viral Hepat; 2005 May; 12(3):223-35. PubMed ID: 15850462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse response to pegylated interferon therapy in two patients with chronic hepatitis C.
    Thomas WL; Ramos F; Hospenthal DR
    Hawaii Med J; 2003 Aug; 62(8):163-4. PubMed ID: 14533347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C.
    Rakov NE
    N Engl J Med; 2003 Jan; 348(3):259-60; author reply 259-60. PubMed ID: 12529472
    [No Abstract]   [Full Text] [Related]  

  • 39. Compare trial: updated data.
    Silva MO
    J Hepatol; 2008 Aug; 49(2):288-9. PubMed ID: 18571269
    [No Abstract]   [Full Text] [Related]  

  • 40. Interferon-alpha induced severe thrombocytopenia: a case report and review of the literature.
    Li L; Han DK; Lu J
    World J Gastroenterol; 2010 Mar; 16(11):1414-7. PubMed ID: 20238410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.